Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

ASCO Connection

Effective May 2021, The Oncology Practice Insider newsletter consolidated with the ASCO Connection newsletter.

ASCO provides the latest news, information, and educational tools to assist with the successful management of oncology practice and the delivery of high-quality patient care, including updates on ASCO programs, services, and cancer-related health policy, Medicare news, and billing and coding best practices. The biweekly ASCO Connection newsletter features the latest information on ASCO programs and resources for every member of the oncology community, including information tailored for practice administrators and practice leaders. Subscribe to the ASCO Connection newsletter for Practice News updates.

Date
On September 14, 2021, the Food and Drug Administration granted accelerated approval to zanubrutinib (Brukinsa, BeiGene) for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen. Read more. 
By November 1, 2021, the Centers for Medicare and Medicaid (CMS) will begin reprocessing claims for outpatient clinic visit services provided at excepted off-campus Provider-Based Departments (PBDs) so they are paid at the same rate as non-excepted off-campus PBDs for those services under the Physician Fee Schedule (PFS). This affects certain claims with dates of service between January 1 - December 31, 2019.
The Biden administration announced that the U.S. Department of Health and Human Services (HHS), through the Health Resources and Services Administration (HRSA), is making $25.5 billion in new funding available for health care providers affected by the COVID-19 pandemic. Read more.  Important to note:
On August 31, 2021, the Food and Drug Administration approved zanubrutinib (Brukinsa, BeiGene) for adult patients with Waldenström’s macroglobulinemia (WM). Read more. 
ASCO is researching the needs of Physician Assistants, Nurse Practitioners, and other Advanced Practice Providers to better understand your thoughts and impressions of the services that ASCO can offer you. The survey should take less than 10 minutes to complete. Your participation is voluntary but critical to the success of the study. Your responses will be kept anonymous and only looked at in the aggregate of your peers and colleagues. Take the Survey  
The Office of the National Coordinator for Health Information Technology (ONC) is hosting a series of webinars to discuss the information blocking requirements of the 21st Century Cures Act. This initial webinar is a physician-focused presentation covering key aspects of their regulations focused on information blocking and is an opportunity to ask questions and get answers from ONC’s experts. This webinar will be held on September 14, 2021 from 1:00 – 2:00 PM ET. Register for the webinar.
On August 17, 2021, the Food and Drug Administration granted accelerated approval to dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options. Read more.   
The Centers for Medicare & Medicare Services (CMS) will be updating the Merit-based Incentive Payment System (MIPS) performance feedback and final scores for some clinicians for performance year 2020 and the associated MIPS payment adjustment information for payment year 2022.